FIELD: medicine.
SUBSTANCE: substance of polypeptide nature with molecular weight 14350 Da, with N-end amino acid sequence, homologous phospholipase A2 of snake venom, and possessing properties of direct thrombin inhibitor of mixed type as well as antiproliferative action is separated of cobra venom Naja haje by three-stage liquid chromatography.
EFFECT: invention enables to produce selective direct thrombin inhibitor, possessing antiproliferative action.
1 tbl, 3 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF SERUM | 2011 |
|
RU2643957C2 |
| SYNTHETIC PEPTIDE DERIVATIVE EXPRESSING ANTICOAGULANT ACTIVITY | 2007 |
|
RU2377246C2 |
| METHOD OF PRODUCTION OF PLASMINOGEN ACTIVATOR | 2007 |
|
RU2346983C1 |
| METHOD OF ISOLATION OF ENDONUCLEASE FROM COBRA VENOM | 2013 |
|
RU2515924C1 |
| METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
| METHOD FOR DETERMINATION OF FUNCTIONAL FIBRINOGEN | 2017 |
|
RU2669796C1 |
| APTAMER OLIGONUCLEOTIDE - DIRECT THROMBIN INHIBITOR | 2008 |
|
RU2401306C2 |
| HIGHLY-SELECTIVE INFESTIN 4-BASED INHIBITOR OF CONTACT ACTIVATION | 2013 |
|
RU2556116C2 |
| NOVEL COMPOUNDS POSSESSING ANTICOAGULANT FUNCTION, BASED ON THEM PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOTIC CONDITIONS AND PLASMA-SUBSTITUTING SOLUTION FOR CORRECTION OF HYPERCOAGULATION DISORDERS IN HEMODILUTION | 2007 |
|
RU2353619C2 |
| DETERMINING OF CIRCULATING THROMBIN IN COMPLEMENT ACTIVATION TEST | 2019 |
|
RU2709341C1 |
